1. Home
  2. ENTG vs RPRX Comparison

ENTG vs RPRX Comparison

Compare ENTG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entegris Inc.

ENTG

Entegris Inc.

HOLD

Current Price

$144.01

Market Cap

22.2B

Sector

Industrials

ML Signal

HOLD

RPRX

Royalty Pharma plc

HOLD

Current Price

$62.03

Market Cap

25.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTG
RPRX
Founded
1966
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2B
25.9B
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
ENTG
RPRX
Price
$144.01
$62.03
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$133.67
$51.40
AVG Volume (30 Days)
2.4M
2.7M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
0.27%
1.90%
EPS Growth
N/A
N/A
EPS
1.21
0.71
Revenue
$3,196,600,000.00
$2,378,193,000.00
Revenue This Year
$9.27
$38.63
Revenue Next Year
$9.50
$4.73
P/E Ratio
$117.74
$87.04
Revenue Growth
N/A
5.06
52 Week Low
$67.97
$34.63
52 Week High
$186.94
$62.46

Technical Indicators

Market Signals
Indicator
ENTG
RPRX
Relative Strength Index (RSI) 51.24 60.32
Support Level $125.45 $56.36
Resistance Level $154.97 N/A
Average True Range (ATR) 6.08 1.26
MACD -0.91 0.20
Stochastic Oscillator 35.95 79.07

Price Performance

Historical Comparison
ENTG
RPRX

About ENTG Entegris Inc.

Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: